ArticleScientific reports2025
The impact of axillary lymph node dissection on the prognosis of breast cancer patients undergoing up-front mastectomy with Sentinel lymph node micrometastases.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Influencing factors of axillary lymph node metastasis and prognosis in patients with T2 breast cancer.Gland surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditionally, completion axillary lymph node dissection (ALND) has been standard for breast cancer patients with positive sentinel lymph nodes (SLNs). However, ALND poses risks of morbidity. Recent trials suggest omission of ALND may be safe in selected cases. Controversy exists regarding ALND omission in mastectomy patients with micrometastases. We retrospectively analyzed data from 12 centers in China and the Surveillance, Epidemiology, and End Results (SEER) database. Patients with T1-2 breast cancer and SLN micrometastases who underwent up-front mastectomy were included. Patients were categorized into two groups: Non-ALND and ALND. Clinicopathological factors and survival outcomes were compared between the two groups. A total of 118 patients from 12 centers in China and 4,884 patients from the SEER database were included in the analysis. The Non-ALND group demonstrated non-inferiority in terms of recurrence-free survival (RFS), locoregional recurrence-free survival (LRFS), breast cancer-specific survival (BCSS), and overall survival (OS) when compared to the ALND group. Multivariable analysis identified significant predictors of survival outcomes. This study supports the omission of ALND in T1-2N1mi breast cancer patients undergoing mastectomy, demonstrating comparable survival outcomes to those undergoing ALND. Proper patient selection is essential for tailored treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.